1256490-31-9

Basic information

• Product Name: N-[(S)-(4-Nitrophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester
• Synonyms: N-[(S)-(4-Nitrophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester;L-Alanine, N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-, 1-Methylethyl ester;2. N-[(S)-(4-Nitrophenoxy)phenoxyphosphinyl]-L-alanine;N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-alanine 1-methylethyl este;isopropyl((S)-(4-nitrophenoxy)(phenoxy)phosphoryl)-L-alaninate;(S)-Isopropyl 2-(((S)-(4-nitrophenoxy)(phenoxy)phosphoryl)amino)propanoate;EOS-61207
• CAS NO: 1256490-31-9
• Molecular Formula: C₁₈H₂₁N₂O₇P
• Molecular Weight: 408.342301
• EINECS: 1312995-182-4
• Mol File: 1256490-31-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 62-66℃
• Boiling Point: 514.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.302
• Storage Temp.: 2-8°C
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• PKA: -5.78±0.70(Predicted)
• CAS DataBase Reference: N-[(S)-(4-Nitrophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(S)-(4-Nitrophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester(1256490-31-9)
• EPA Substance Registry System: N-[(S)-(4-Nitrophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester(1256490-31-9)

Safety Data

• Hazardous Substances Data: 1256490-31-9(Hazardous Substances Data)

Usage

Uses

N-[(S)-(4-Nitrophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl Ester is an intermediate in the synthesis of Sofosbuvir (R)-Phosphate (S675615), which is an impurity of PSI-7977 (P839640), a prodrug that is metabolized to the active antiviral agent 2''-deoxy-2''-α-fluoro-β-C-methyluridine-5''-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.

Upstream product

• 1256490-48-8 (S)-2-[(4-nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid isopropyl ester 
• 777-52-6 1-dichlorophosphoryloxy-4-nitro-benzene 
• 793-10-2 p-nitrophenyl phenyl phosphorochloridate 
• 39613-92-8 alanine isopropyl ester hydrochloride 
• 108-95-2 phenol 
• 770-12-7 O-phenyl phosphorodichloridate 
• 100-02-7 4-nitro-phenol 
• 39825-33-7 isopropyl L-alanine 

Downstream Products

• 1190307-88-0 sofosbuvir 
• 1190308-01-0 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy](phenoxy)phosphorylamino}propionic acid isopropyl ester 
• 1334513-09-5 (S)-isopropyl 2-(((S)-(((3aR,4R,6R,6aR)-6-(6-amino-0H-purin-9-yl)-2,2-dimethyltetrahydrofuro-[3,4-d]dioxol-4-yl)methoxy)(phenoxy)phosphoryl)amino)propionoate 
• 1354823-59-8 (Sp)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate 
• 1402822-33-6 (2S)-isopropyl2-(((S)-((1R)-1-((3aR,4S,6R,6aR)-6-(4-amino-2-oxopyrimidin-1(2H)-yl)-6-cyano-2-methoxytetrahydrofuro[3,4-d][1,3]dioxol-4-yl)ethoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1402822-34-7 (S)-isopropyl2-(((S)-((R)-1-((2S,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)ethoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1402822-30-3 C₂₃H₃₀N₅O₉P 
• 1402822-37-0 C₂₇H₃₆N₅O₁₀P 
• 1402822-31-4 (S)-isopropyl2-(((S)-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1402822-36-9 C₂₃H₂₉N₄O₁₀P 
• 1350735-70-4 [(Sp)-isopropyl 2-((S)-(((2R,3R,4R,5R)-3-isobutyroxy-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy) (phenoxy)phosphorylamino)propanoate] 

Relevant articles and documents

Enzyme-Catalyzed Kinetic Resolution of Chiral Precursors to Antiviral Prodrugs

Nucleoside analogues are among the most common medications given for the treatment of viral infections and cancers. The therapeutic effectiveness of nucleoside analogues can be dramatically improved by phosphorylation. The ProTide approach was developed u

(S)- 2 - [(s)- (4 - nitro - phenoxy) - phenoxy - phosphoryl amino] isopropyl propionate preparation method

The invention relates to a preparation method of (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate. The (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate, which is excellent in chemical purity and optical purity, is prepared by the following steps: preparing a compound as shown in a formula (III) from phenoxy dichlorophosphite as shown in a formula (I) and nitrophenol as shown in a formula (II), preparing a compound as shown in formula (V) from the compound as shown in the formula (III) and L-alanine isopropyl ester hydrochloride, and implementing solvent recrystallization on the compound as shown in the formula (V). The preparation method disclosed by the invention has the beneficial effects that the method for preparing the (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate is simple in technological process and convenient to operate, and meanwhile the method is high in both purity and yield and is applicable to mass production.

DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

The invention provides compounds of formula (I), wherein: R1 is OR11, or NR5R5'; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.